Product news

Share this article:
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

Trudell Medical International announced FDA approval of Alvesco (ciclesonide) inhalation aerosol in combination with the Aerocount Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the US by Sepracor under an agreement with Nycomed based in Europe. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.